Latest Safety News

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

Imricor Medical Systems has secured CE Mark approval for its NorthStar Mapping System ahead of schedule, marking a pivotal shift to software-centric MRI-guided cardiac interventions across Europe and the Middle East.

Lefroy Exploration has secured its inaugural toll milling agreement for the Lucky Strike Gold Project, marking a significant step towards production with a February 2026 milling slot at Greenfields Mill.

Clarity Pharmaceuticals reports that its Cu-SARTATE diagnostic agent significantly outperforms the current standard in detecting neuroendocrine tumours, paving the way for a pivotal Phase III study.

Lanthanein Resources is set to raise $2.4 million through a placement and a fully underwritten rights issue, while proposing a strategic name change and share consolidation to streamline its capital structure.

Lotus Resources has secured Environmental and Social Impact Assessment approval for its Kayelekera Uranium Project in Malawi, paving the way for uranium production to resume in the third quarter of 2025. The company also completed a key board transition, signaling a new phase in its governance.

Lindian Resources reports significant construction progress at its Kangankunde Rare Earths Project in Malawi, alongside strategic site leadership appointments as it gears up for plant construction later this year.

Nyrada has secured ethics approval to amend its Phase I clinical trial protocol for Xolatryp, allowing testing of higher doses and extended infusion times. This strategic move aims to refine dosing ahead of Phase II trials, with final Phase I results expected by September 2025.

Chimeric Therapeutics has secured FDA Fast Track designation for its CHM CDH17 CAR-T therapy targeting gastroenteropancreatic neuroendocrine tumours, accelerating its path toward regulatory approval and patient access.

Radiopharm Theranostics has initiated dosing in its Phase 1 HEAT trial of 177Lu-RAD202, a novel radiotherapeutic aimed at advanced HER2-positive solid tumors, marking a key step in its clinical development.

I Synergy Group Limited has announced a fully underwritten pro-rata renounceable entitlement offer to raise up to $1 million, aiming to bolster working capital and fund key operational initiatives. The offer, underwritten by VGI Vmall Limited, will significantly increase the company's shares on issue, with potential dilution risks for non-participating shareholders.

I Synergy Group Limited has announced a renounceable entitlement offer aiming to raise approximately $1 million to fund new projects and operational growth. The offer is fully underwritten and open to shareholders across multiple Asia-Pacific markets.